Is enGene Therapeutics, Inc. ENGN stock Halal to invest in?

No, as of September 2026, enGene Therapeutics, Inc. stock (ENGN) is not currently classified as a Shariah compliant stock. This verdict follows the screening methodology of AAOIFI (the Accounting and Auditing Organization for Islamic Financial Institutions), whose Shariah Standard No. 21 is the leading global benchmark for screening Halal stocks. To qualify as Halal under this standard, a company must keep non-permissible income below 5% of total revenue, keep both interest-bearing investments and interest-bearing debt below 30% of market capitalisation, and have no impermissible preference share structure. enGene Therapeutics, Inc. currently does not meet the threshold for the non-permissible income and interest-bearing investments screens. Because screenings are refreshed monthly as new financial reports are published, a non-compliant stock can regain compliant status if its financial structure changes. You can track the latest status of enGene Therapeutics, Inc. and discover Shariah compliant alternatives among the Halal stocks in the Tabadulat app.

How often is enGene Therapeutics, Inc. ENGN reviewed for Shariah compliance?

Tabadulat reviews enGene Therapeutics, Inc. ENGN for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for enGene Therapeutics, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does enGene Therapeutics, Inc. ENGN pass the AAOIFI Non Permissible Income criteria?

No, as of September 2026, enGene Therapeutics, Inc. stock (ENGN) does not pass the AAOIFI non-permissible income screen. Under AAOIFI Shariah Standard No. 21, income from impermissible sources (such as interest or Riba, conventional financial services, alcohol, gambling, or tobacco) must remain below 5% of a company's total revenue. enGene Therapeutics, Inc.'s income from non-permissible sources currently exceeds this 5% ceiling, which makes the stock non-compliant on this criterion regardless of how it performs on the other screens. The screen is reassessed monthly, so the status can change when the company releases new financial statements.

Does enGene Therapeutics, Inc. ENGN pass the AAOIFI Interest Bearing Investments criteria?

No, as of September 2026, enGene Therapeutics, Inc. stock (ENGN) does not pass the AAOIFI interest-bearing investments screen. Under AAOIFI Shariah Standard No. 21, the cash a company places in interest-earning instruments (such as conventional deposits, bonds, treasury bills and money-market funds) must remain below 30% of its market capitalisation. enGene Therapeutics, Inc.'s interest-bearing investments currently exceed this 30% limit, meaning too large a share of the company's value derives from Riba-based instruments for the stock to qualify as Halal on this criterion. The ratio moves with both the balance sheet and the share price, and is reassessed monthly.

Does enGene Therapeutics, Inc. ENGN pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of September 2026, enGene Therapeutics, Inc. stock (ENGN) passes the AAOIFI interest-bearing debt screen. Each month Tabadulat measures enGene Therapeutics, Inc.'s interest-accruing borrowings against AAOIFI's 30% market capitalisation cap. The current screening shows the company within the limit, so the debt screen passes. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for enGene Therapeutics, Inc. ENGN stock?

enGene Therapeutics, Inc. (ENGN) is currently classified as not Shariah compliant, so no dividend purification factor applies, because purification factors are calculated only for stocks that pass the AAOIFI screens. Purification (Tazkiyah) is the practice of donating to charity the small portion of dividend income that stems from incidental non-permissible sources, such as interest earned on a compliant company's cash deposits. For non-compliant stocks the issue is not purification but eligibility: under AAOIFI Shariah Standard No. 21 the stock does not currently qualify as a Halal investment. If enGene Therapeutics, Inc. returns to compliance in a future monthly screening, its purification factor will be published alongside its updated status in the Tabadulat app.

Does enGene Therapeutics, Inc. ENGN pass the AAOIFI Preference Share screen?

Yes, as of September 2026, enGene Therapeutics, Inc. stock (ENGN) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. enGene Therapeutics, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Is enGene Therapeutics (ENGN) stock Halal?

NASDAQ

Shariah-Compliant

Not Shariah

As of the September 2026 screening, enGene Therapeutics, Inc. (ENGN) does not meet the AAOIFI Shariah Standard No. 21 threshold for the non-permissible income and interest-bearing investments screens, so the stock is not currently classified as Shariah compliant. It is re-screened every month and can regain compliance if its financial structure changes.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

Website:

https://www.engene.com

Market cap:

$127M

P/E ratio:

Dividend yield:

52-week range:

$1.40 - $12.25

Data as of:

3 September 2026

Screening history:

September 2026: FAIL

enGene Therapeutics is a dynamic player in the healthcare sector, focused on the development and commercialization of advanced biopharmaceutical technologies. This company is primarily dedicated to enhancing drug delivery systems which improve the efficacy and safety of existing pharmaceuticals. Engene Holdings Inc.'s proprietary methodologies aim to transform oral and injectable drugs by utilizing its cutting-edge delivery platforms, thereby broadening the scope of treatment options for various medical conditions. For Muslim investors, though, the most pressing question is simpler: is enGene Therapeutics a Halal investment?

Is enGene Therapeutics Shariah compliant?

Technology companies rarely fail AAOIFI screening on what they sell. Software, hardware and digital services are permissible business activities, so for a company like enGene Therapeutics the Shariah question moves to the balance sheet: how much of its market value sits in interest bearing debt, how much of its cash earns Riba in conventional deposits, and whether incidental income from impermissible sources creeps past 5% of revenue. These are exactly the ratios AAOIFI Shariah Standard No. 21 polices, and they move every month with the share price.

Does enGene Therapeutics pass the business activity test?

The activity screen is only part of the picture this month: enGene Therapeutics currently fails the non-permissible income and interest-bearing investments screens, so the overall verdict is not compliant regardless of the business itself. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.

Is enGene Therapeutics' income Halal?

No. enGene Therapeutics' income from impermissible sources currently exceeds AAOIFI's 5% revenue ceiling, which makes the stock non-compliant on this screen regardless of the others. The screen is reassessed monthly, so the status can change when new financial statements arrive.

Does enGene Therapeutics meet AAOIFI's debt and investment ratio requirements?

Not in full. Interest bearing investments currently exceed the 30% cap, while the other ratio stays within it. One breach is enough to fail the screening; the ratios are reassessed monthly under our Shariah Supervisory Board.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the four screens? Read Why a Halal Stock Screener Matters for Halal Investing

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in Halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.